Skip to content
OpenCapital
Get started

Monte Rosa Therapeutics, Inc. GLUE Current ratio

Current ratio at other companies

Bristol-Myers Squibb logo
Bristol-Myers SquibbBMY
1.4×+0.1×
Nurix Therapeutics, Inc. logo
Nurix Therapeutics, Inc.NRIX
6×-0.3×
Kymera Therapeutics logo
Kymera TherapeuticsKYMR
10.8×+2.3×
Immunome logo
ImmunomeIMNM
21.7×+11.2×
Cogent Biosciences, Inc. logo
Cogent Biosciences, Inc.COGT
15.1×+10.0×
Adaptive Biotechnologies logo
Adaptive BiotechnologiesADPT
3.4×+0.4×

Other financials

Income statement

See full
Revenue$4.2M-95.0%
Operating income-$50.0M-214%
Net income-$44.5M-195%
EPS (diluted)-$0.45-179%

Balance sheet

See full
Cash & equivalents$159.9M+104%
Total debt$39.1M-6.7%
Total equity$521.9M+89.7%
Total assets$736.4M+87.3%

Cash flow

See full
Operating cash flow-$37.4M+17.9%
CapEx$1.9M+17.7%
Free cash flow-$39.2M+16.7%

Valuation

See full
Market cap$1.75B+361%
Enterprise value$1.63B+381%
P/S40.7×+38.4×

Profitability

See full
Operating margin-345.2%—
Net margin-302.6%—
FCF margin-45.8%-64.9pp

Returns & leverage

See full
Return on equity-32.6%—
Debt / equity0.1×-0.1×

Where this comes from

Calculated from Monte Rosa Therapeutics, Inc.’s reported figures.

total current assets/total current liabilities=9.5×

Based on the most recent quarter.

The official record: Monte Rosa Therapeutics, Inc.’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Monte Rosa Therapeutics, Inc.'s current ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Monte Rosa Therapeutics, Inc.'s current ratio?
Monte Rosa Therapeutics, Inc. (GLUE) reported current ratio of 9.5× in Q1 2026.
How has Monte Rosa Therapeutics, Inc.'s current ratio changed year-over-year?
Monte Rosa Therapeutics, Inc.'s current ratio increased by 70.0% year-over-year, from 5.6× to 9.5×.
What is the long-term trend for Monte Rosa Therapeutics, Inc.'s current ratio?
Over 5 years (2020 to 2025), Monte Rosa Therapeutics, Inc.'s current ratio has grown at a 32.7% compound annual growth rate (CAGR), from 1.5× to 6.1×.
What does current ratio mean?
Current assets divided by current liabilities at the quarter end. Measures the company's ability to cover near-term obligations with near-term assets.